HRP20050871A2 - Pharmaceutical compositions for hepatitis c viral protease inhibitors - Google Patents
Pharmaceutical compositions for hepatitis c viral protease inhibitorsInfo
- Publication number
- HRP20050871A2 HRP20050871A2 HR20050871A HRP20050871A HRP20050871A2 HR P20050871 A2 HRP20050871 A2 HR P20050871A2 HR 20050871 A HR20050871 A HR 20050871A HR P20050871 A HRP20050871 A HR P20050871A HR P20050871 A2 HRP20050871 A2 HR P20050871A2
- Authority
- HR
- Croatia
- Prior art keywords
- hepatitis
- pharmaceutical compositions
- protease inhibitors
- pharmaceutically acceptable
- viral protease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45976503P | 2003-04-02 | 2003-04-02 | |
PCT/US2004/008837 WO2004093915A1 (en) | 2003-04-02 | 2004-03-23 | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20050871A2 true HRP20050871A2 (en) | 2006-10-31 |
Family
ID=33310709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20050871A HRP20050871A2 (en) | 2003-04-02 | 2005-09-30 | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
Country Status (24)
Country | Link |
---|---|
US (1) | US7157424B2 (es) |
EP (1) | EP1613353A1 (es) |
JP (1) | JP2006522017A (es) |
KR (1) | KR20050108420A (es) |
CN (1) | CN100363055C (es) |
AR (1) | AR043795A1 (es) |
AU (1) | AU2004231538A1 (es) |
BR (1) | BRPI0409068A (es) |
CA (1) | CA2520886A1 (es) |
CO (1) | CO5640152A2 (es) |
EA (1) | EA010013B1 (es) |
EC (1) | ECSP056065A (es) |
HK (1) | HK1091130A1 (es) |
HR (1) | HRP20050871A2 (es) |
MX (1) | MXPA05010338A (es) |
NO (1) | NO20055057L (es) |
NZ (1) | NZ543250A (es) |
PE (1) | PE20050013A1 (es) |
RS (1) | RS20050741A (es) |
TW (1) | TW200505484A (es) |
UA (1) | UA81028C2 (es) |
UY (1) | UY28250A1 (es) |
WO (1) | WO2004093915A1 (es) |
ZA (1) | ZA200506019B (es) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
EA200600498A1 (ru) * | 2003-09-22 | 2006-10-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
ES2358333T3 (es) * | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
CA2552319C (en) | 2004-01-30 | 2012-08-21 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1879607B1 (en) * | 2005-05-02 | 2014-11-12 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI387603B (zh) * | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
JP4705984B2 (ja) * | 2005-08-01 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Hcvns3プロテアーゼ阻害剤としての大環状ペプチド |
CN101415705B (zh) * | 2005-10-11 | 2011-10-26 | 因特蒙公司 | 抑制丙型肝炎病毒复制的化合物和方法 |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US20070281884A1 (en) * | 2006-06-06 | 2007-12-06 | Ying Sun | Macrocyclic oximyl hepatitis C protease inhibitors |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
US8138164B2 (en) * | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2008051477A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
CN101568346B (zh) | 2006-10-27 | 2015-11-25 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
KR101615500B1 (ko) * | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | Hcv ns3 프로테아제 억제제 |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0625345D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
AU2007335962B2 (en) * | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
EP2185524A1 (en) * | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
WO2009010785A1 (en) * | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
CA2699891C (en) | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
GB2451811A (en) * | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
US8030307B2 (en) | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
EP2224920A4 (en) | 2007-12-06 | 2012-05-09 | Enanta Pharm Inc | PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
AU2009217551B2 (en) | 2008-02-25 | 2014-07-31 | Msd Italia S.R.L. | Therapeutic compounds |
MX2010011306A (es) | 2008-04-15 | 2010-11-09 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c. |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2271345B1 (en) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
CN102159285B (zh) | 2008-07-22 | 2014-05-14 | 默沙东公司 | 作为hcv ns3蛋白酶抑制剂的大环喹喔啉化合物 |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2011006631A (es) | 2008-12-19 | 2011-09-06 | Gilead Sciences Inc | Inhibidores de proteasa ns3 del virus hcv. |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
MA33491B1 (fr) | 2009-07-07 | 2012-08-01 | Boehringer Ingelheim Int | Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c |
US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
CN104771364B (zh) * | 2010-03-10 | 2018-05-25 | 艾伯维巴哈马有限公司 | 固体组合物 |
JP5906253B2 (ja) * | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
CN103380132B (zh) | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
JP2014502620A (ja) | 2010-12-30 | 2014-02-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状c型肝炎セリンプロテアーゼ阻害剤 |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US20120213855A1 (en) * | 2011-02-17 | 2012-08-23 | Cima Labs Inc. | Dosage forms for weakly ionizable compounds |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2723337A1 (en) | 2011-06-23 | 2014-04-30 | Panmed Ltd. | Treatment of hepatitis c virus |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
EP2903988A1 (en) | 2012-10-08 | 2015-08-12 | AbbVie Inc. | Compounds useful for making hcv protease inhibitors |
LT2909205T (lt) | 2012-10-19 | 2016-12-27 | Bristol-Myers Squibb Company | 9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070974A1 (en) * | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
CN103965286B (zh) * | 2014-04-22 | 2017-11-03 | 南京安赛莱医药科技有限公司 | 丙型肝炎病毒(hcv)ns3蛋白酶抑制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0989851T3 (da) * | 1997-07-29 | 2003-01-27 | Upjohn Co | Selvemulgerende formulering indeholdende sure lipofile forbindelser |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
EA200600498A1 (ru) * | 2003-09-22 | 2006-10-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с |
-
2004
- 2004-03-23 RS YUP-2005/0741A patent/RS20050741A/sr unknown
- 2004-03-23 CA CA002520886A patent/CA2520886A1/en not_active Abandoned
- 2004-03-23 US US10/807,023 patent/US7157424B2/en active Active
- 2004-03-23 AU AU2004231538A patent/AU2004231538A1/en not_active Abandoned
- 2004-03-23 EP EP04759731A patent/EP1613353A1/en not_active Withdrawn
- 2004-03-23 NZ NZ543250A patent/NZ543250A/en unknown
- 2004-03-23 KR KR1020057018703A patent/KR20050108420A/ko not_active Application Discontinuation
- 2004-03-23 CN CNB2004800087739A patent/CN100363055C/zh not_active Expired - Fee Related
- 2004-03-23 UA UAA200510334A patent/UA81028C2/uk unknown
- 2004-03-23 MX MXPA05010338A patent/MXPA05010338A/es active IP Right Grant
- 2004-03-23 EA EA200501532A patent/EA010013B1/ru not_active IP Right Cessation
- 2004-03-23 BR BRPI0409068-3A patent/BRPI0409068A/pt not_active IP Right Cessation
- 2004-03-23 WO PCT/US2004/008837 patent/WO2004093915A1/en active Application Filing
- 2004-03-23 JP JP2006501244A patent/JP2006522017A/ja active Pending
- 2004-03-31 TW TW093108968A patent/TW200505484A/zh unknown
- 2004-03-31 AR ARP040101067A patent/AR043795A1/es active Pending
- 2004-03-31 PE PE2004000340A patent/PE20050013A1/es not_active Application Discontinuation
- 2004-03-31 UY UY28250A patent/UY28250A1/es not_active Application Discontinuation
-
2005
- 2005-07-27 ZA ZA200506019A patent/ZA200506019B/en unknown
- 2005-09-30 HR HR20050871A patent/HRP20050871A2/xx not_active Application Discontinuation
- 2005-09-30 EC EC2005006065A patent/ECSP056065A/es unknown
- 2005-10-28 CO CO05110321A patent/CO5640152A2/es not_active Application Discontinuation
- 2005-10-31 NO NO20055057A patent/NO20055057L/no not_active Application Discontinuation
-
2006
- 2006-10-26 HK HK06111837A patent/HK1091130A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1091130A1 (en) | 2007-01-12 |
EP1613353A1 (en) | 2006-01-11 |
UA81028C2 (en) | 2007-11-26 |
EA200501532A1 (ru) | 2006-06-30 |
CN1767856A (zh) | 2006-05-03 |
JP2006522017A (ja) | 2006-09-28 |
PE20050013A1 (es) | 2005-03-01 |
BRPI0409068A (pt) | 2006-03-28 |
CO5640152A2 (es) | 2006-05-31 |
EA010013B1 (ru) | 2008-06-30 |
CA2520886A1 (en) | 2004-11-04 |
WO2004093915A1 (en) | 2004-11-04 |
CN100363055C (zh) | 2008-01-23 |
NO20055057L (no) | 2005-10-31 |
ZA200506019B (en) | 2006-07-26 |
NZ543250A (en) | 2008-12-24 |
KR20050108420A (ko) | 2005-11-16 |
MXPA05010338A (es) | 2005-11-17 |
ECSP056065A (es) | 2006-01-27 |
AU2004231538A1 (en) | 2004-11-04 |
RS20050741A (en) | 2007-06-04 |
AR043795A1 (es) | 2005-08-10 |
TW200505484A (en) | 2005-02-16 |
US7157424B2 (en) | 2007-01-02 |
US20040229776A1 (en) | 2004-11-18 |
UY28250A1 (es) | 2004-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050871A2 (en) | Pharmaceutical compositions for hepatitis c viral protease inhibitors | |
EA200400991A1 (ru) | Фармацевтические композиции, содержащие ингибиторы протеазы вируса гепатита c | |
EA200800178A1 (ru) | Ингибиторы вируса гепатита с (hcv) | |
DK1066247T3 (da) | Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease | |
CU20080057A7 (es) | Compuestos y métodos para inhibir la replicación de hepatitis c viral | |
ATE474827T1 (de) | Hcv-replikationshemmer | |
BR0311132A (pt) | Inibidores do vìrus da hepatite c | |
TWI265927B (en) | Novel compounds as NS3-serine protease inhibitors of hepatitis C virus | |
DK1556021T3 (da) | Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger | |
NO20044897L (no) | Hepatitt C virus inhibitorer | |
UY35542A (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
IS7532A (is) | Heterósýklískir súlfónamíð lifrarbólgu C-veirutálmar | |
EA200701669A1 (ru) | Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae | |
BR9712544A (pt) | Inibidores de proteases de serina, particularmente protease ns3 do vìrus hapatite c | |
ECSP066794A (es) | Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
ZA200900935B (en) | Hepatitis C virus inhibitors | |
PL378107A1 (pl) | 1,2,4-triazyny hamujące HIV | |
ATE327246T1 (de) | Hepatitis c tripeptid inhibitoren | |
EA200600227A1 (ru) | Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов | |
SV2007002309A (es) | Compuestos 5-nitro-nucleosidos para tratar infecciones virales | |
TW200744625A (en) | HCV inhibitors | |
GT200400180A (es) | Combinacion de inhibidores de la recaptacion de serotonina e inhibidores de la recaptacion de norepinefrina. | |
TW200716123A (en) | Pteridines useful as HCV inhibitors and methods for the preparation thereof | |
WO2001095896A3 (en) | Protein phosphatase 2a inhibitors to inhibit host-cell mediated viral replication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090320 Year of fee payment: 6 |
|
OBST | Application withdrawn |